-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 3% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have exon 18 mutations
About 3% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have exon 18 mutations
Retrospective analysis of studies receiving first-generation (1G) EGFR-tyrosine kinase inhibitor (TKI), second-generation (2G) EGFR-TKI afatinib, chemotherapy, and 1G between May 2014 and September 2020 Clinical outcomes of 82 patients with EGFR exon 18 mutation who received TKI combined with chemotherapy as initial therapy
Retrospective analysis of studies receiving first-generation (1G) EGFR-tyrosine kinase inhibitor (TKI), second-generation (2G) EGFR-TKI afatinib, chemotherapy, and 1G between May 2014 and September 2020 Clinical outcomes of 82 patients with EGFR exon 18 mutation who received TKI combined with chemotherapy as initial therapy
A total of 82 patients with EGFR 18-mutated NSCLC were analyzed for treatment and survival outcomes
Among 20 patients with baseline neurological (CNS) metastases at initial diagnosis, the most common EGFR exon 18 mutation subtypes were G719X (n = 16, 80%) and E709_T710delinsD (n = 2, 10%)
Among 20 patients with baseline neurological (CNS) metastases at initial diagnosis, the most common EGFR exon 18 mutation subtypes were G719X (n = 16, 80%) and E709_T710delinsD (n = 2, 10%)
Of the 82 patients, 24 received 1G EGFR-TKI, 21 received afatinib, 22 received chemotherapy, and 15 received 1G EGFR-TKI combined with chemotherapy
Univariate analysis showed that PFS in patients with advanced NSCLC with EGFR exon 18 mutation was significantly associated with molecular subtype (P < 0.
Univariate analysis showed that PFS in patients with advanced NSCLC with EGFR exon 18 mutation was significantly associated with molecular subtype (P < 0.
Multivariate analysis confirmed that the molecular subtype and treatment pattern of EGFR exon 18 were independent predictors of PFS in advanced NSCLC patients with EGFR exon 18 (P<0.
Multivariate analysis confirmed that the molecular subtype and treatment pattern of EGFR exon 18 were independent predictors of PFS in advanced NSCLC patients with EGFR exon 18 (P<0.
In conclusion, the study shows that for patients with EGFR exon 18 mutant NSCLC, first-generation EGFR TKI combined with chemotherapy and afatinib may be the best treatment
In conclusion, the study shows that for patients with EGFR exon 18 mutant NSCLC, first-generation EGFR TKI combined with chemotherapy and afatinib may be the best treatment
Original source:
Original source:Xu H, Yang G, Li W, LiJ, Hao X, Xing P, Yang Y and Wang Y (2021) EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes .
Xu H, Yang G, Li W, LiJ, Hao X, Xing P, Yang Y and Wang Y (2021) EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes .
Front.
Oncol.
11:713483.
doi: 10.
3389/fonc.
2021.
713483
Leave a comment here
